C-MER Medical (HKG:3309) expects a loss attributable to equity holders between HK$130 million and HK$160 million in 2024, against a profit of HK$62 million logged in 2023, a Wednesday Hong Kong bourse filing said.
The company attributed the expected swing to loss to certain impairments on goodwill, property, plant, equipment, and the group's right-of-use assets resulting from weaker performance from some hospitals, market competition, and a weakened consumer sentiment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。